Imprint
Content
Dr. Erkens Consulting Group
Industriestraße 13
D- 64380 Roßdorf
Germany
Tel: +49 6154 – 69 67 944 • Mobil +49 179 – 2 41 10 29
Message to Dr. Erkens Consulting Group
tax no. 73 841 210 966
Webmaster
be-sign.net • Bernd Scheurer
Mainstr. 2, 64390 Erzhausen
Tel.: +49 151 – 50 411 034
Message to Webmaster
Web: www.be-sign.net
Scripting
Stefan Klose
(M.Sc. Informatik)
Copyrights
Unless otherwise stated, the copyright of the photos used lies with Dr. Erkens Consulting Group.
The corresponding statutory provisions apply to all registered brands, trade names and logos used on our website, even if they are not marked as such in the respective places.
- Photo Home: ABWI74/pixabay
- Photo Business area Strategie | Consulting: Headway/unsplash
- Photo Business area Management | Leadership: Marten van den Heuvel/unsplash
- Photo Business area Analyses | Market research: Carlos Muza/unsplash
- Photo Business area Marketing | Sales: Diggity Marketing/unsplash
- Photo Business area Communication | Education: Marko Pekić/unsplash
- Photo News: Andrys/pixabay
- Photo Company: Dagobert1980/pixabay
- Photo: Meeting: jmexclusives/pixabay
- Photo: Microscope: kkolosov/pixabay
- Photo Services: paulbr74/pixabay
- Photo Network: StockSnap/pixabay
- Photo Academy: plugrafico/pixabay
- Photo Blog: Free-Photos/pixabay
- Photo: Career: rolandmey/pixabay
- Photo Contact: Skitterphoto/pixabay
- Photo MediaCenter: JESHOOTS-com/pixabay
- Photo GTC, Imprint, Privacy: Cleverpix/pixabay
Adress
Dr. Erkens Consulting Group
Industriestraße 13
64380 Roßdorf
Tel: +49 (0)6154 – 6967 – 944
Mobil +49 (0)179 – 2 41 10 29
info@dr-erkens-consulting.de
News
Dr. Erkens Consulting Group
- Website-Relaunch of Dr. Erkens Consulting Group
Source: Dr. Erkens Consulting Group 09/2020 - Integrated Pharma-News at Dr. Erkens Consulting Group Website
Source: Dr. Erkens Consulting Group 09/2020
Pharma Letter
- Accord’s Stelara biosimilar Imuldosa wins positive CHMP recommendation
- Seaport Therapeutics closes $225 million financing
- Oral semaglutide shows 14% reduction in risk of major adverse CD events
- OncoZenge and Pharmanovia deal on BupiZenge in EMENA
- Gilead and Merck tout first weekly oral HIV treatment
Pharma Relations
Pharma Times
- NICE recommends Santen’s Roclanda to treat glaucoma and ocular hypertension
- Learna and University of Wolverhampton launch flexible healthcare courses
- New £4.5m initiative launched to address UK medicines manufacturing skills shortage
- Vivan renews five-year lease at UK biotech hub White City Place
- HBC Immunology shares promising results for prostate cancer co-therapy
PZ online
- Selbsthilfe und Unterstützung: So bleiben Angehörige von psychisch Erkrankten selbst gesund
- Häufige Arzneistoffe: Steckbrief Tamoxifen
- Analyse von Lieferengpässen: AOK sieht keinen Grund zur Sorge
- OTC-Switch: Viagra und Co. ohne Rezept?
- Neue EU-Abwasserrichtlinie: Pro-Generika warnt vor »Tsunami an Engpässen«
Our Place on Earth
Kartenbild: OpenStreetMap, ODbL 1.0